UVA Health has joined a nationwide study evaluating two recycling drugs in search of effective, safe treatments for mild to moderate COVID-19. Recycled drugs are already approved by the U.S. Food and Drug Administration for the treatment of other diseases or conditions.
ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a nationwide, double-blind study that is expected to include nearly 15,000 participants from across the United States. A double-blind study means that both study participants and researchers do not know what medication the participants are receiving as part of the trial.
Residents from across Virginia and across the United States can learn more about participating in the trial by visiting activ6study.org or calling 833-385-1880. Volunteers in the trial can participate from home.
The study is now testing these recycled drugs:
“Although we have some amazing new drugs for COVID-19 in outpatients, such as Paxlovid and sotrovimab, supplies are limited and it is still important to find potential new treatments,” said Dr. Patrick EH Jackson, Principal Investigator for the clinical trial at UVA Health. “Because the drugs we study are inexpensive and widely available, they can have a huge global impact if we find them effective for COVID treatment.”
Eligibility and trial participation
To be eligible, participants must be 30 years or older, have had a positive COVID-19 test within the past 10 days, and have had at least two symptoms of the disease for seven days or less. Symptoms include fatigue, difficulty breathing, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms and / or new loss of taste or smell.
Participation involves taking the medication and keeping track of symptoms over 90 days through online examinations. Medicine is sent free of charge to the participants.
The study is part of the National Institutes of Health-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines initiative led by the National Center for Advancing Translational Sciences.